
ANI Pharma (ANIP) Stock Forecast & Price Target
ANI Pharma (ANIP) Analyst Ratings
Bulls say
ANI Pharmaceuticals Inc is experiencing robust growth in the ACTH gel market and anticipates further increases in operating margin, projecting an adjusted operating margin growth from 25.4% in 2024 to 29.7% by 2028. The company expects to generate over $630 million in operating cash flow from 2025 to 2028, bolstered by strong revenue performance in recent quarters and positive demand for key products. Additionally, increased prescription volumes for new launches and anticipated positive contributions from legacy brands and generics are driving upward revisions in revenue estimates, supporting a favorable outlook for the company's financial performance.
Bears say
ANI Pharmaceuticals has witnessed a notable decline in revenue within its Brands segment during the second and third quarters of 2024, attributed to changing market conditions for certain molecules and specific pricing pressures faced by its flagship product, Cortrophin. The company's revenue estimates for 1Q 2025 have been adjusted downward, reflecting an anticipated steep decline due to seasonal factors and Medicare-related issues, exacerbated by reduced funding from non-profit foundations that support co-pays for Medicare patients. Despite reporting total revenue of $190.6 million in the preceding quarter, which exceeded expectations, ongoing access challenges and pricing headwinds raise concerns about the sustainability of revenue growth moving forward.
This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares